ROCKVILLE, Md., Aug. 24 /PRNewswire-FirstCall/ -- Stem cell company Neuralstem, Inc. (OTC Bulletin Board: NRLS) today announced that its shares have been accepted for listing on the American Stock Exchange(R) (Amex(R)) under the symbol CUR. Neuralstem shares are expected to begin trading on Amex on August 27, 2007.
"Moving to the Amex is the next logical step for Neuralstem. It is a result of the continuous and significant progress the company has made in each and every phase of its activity, and of an increasing awareness of the company and its prospects on the part of the financial community," said Richard Garr, Neuralstem President and Chief Executive Officer.
The approval is contingent upon the company being in compliance with all applicable listing standards on the date its stock begins trading on the Amex(R) and may be rescinded if the company is not in compliance with such standards.
Neuralstem's patent-protected technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. The Company expects that its first Investigational New Drug (IND) application will be for the treatment of Ischemic Paraplegia, a form of paraplegia that sometimes results from the surgery to repair aortic aneurysms and for which there is no effective treatment The Company hopes to submit its initial IND application to the FDA and begin its first human trial during calendar year 2007.
Major Central Nervous System diseases targeted by the Company with
research programs currently underway include: Ischemic Paraplegia,
Traumatic Spinal Cord Injury, ALS, and Parkinson's disease. The company's
cells recently extended the life of rats with ALS (Lou Gehrig's disease) in
a paper published in the journal TRANSPLANTATION, and were deemed viable
|SOURCE Neuralstem, Inc.|
Copyright©2007 PR Newswire.
All rights reserved